David Lucas M. PhD

David Lucas M. PhD
Res Asst ProfessorCollege of Medicinelucas.194@osu.edu
455D Comprehensive Cancer Center 410 W 12th Avenue Columbus Ohio 43210
Phone:614-292-8154Fax:
  • Leukemia Research

Research Description

Dr. Lucas' research interests include Pharmacology of novel anti-leukemic agents, role of transcriptional and translational regulation in tumor cell survival and drug resistance

Current Publications

  • El-Elimat T, Raja HA, Figueroa M, Swanson SM, Falkinham Iii JO, Lucas DM, Grever MR, Wani MC, Pearce CJ, Oberlies NHSorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album.J Antibiot (Tokyo) in press 9/24/2014
  • Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC, Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JRValidation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.Blood 124 42-8 7/3/2014
  • Pan L, Woodard JL, Lucas DM, Fuchs JR, Kinghorn ADRocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.Nat Prod Rep 31 924-39 7/1/2014
  • Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Johnson AJ, Byrd JC, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski GProlonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.Blood 123 1810-7 3/20/2014
  • Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, Jordan CTFlavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.Leukemia in press 2/28/2014
  • Singh R, Mortazavi A, Telu KH, Nagarajan P, Lucas DM, Thomas-Ahner JM, Clinton SK, Byrd JC, Freitas MA, Parthun MRIncreasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis.Nucleic Acids Res 41 9284-95 11/1/2013
  • Bueno Pérez L, Pan L, Sass E, Gupta SV, Lehman A, Kinghorn AD, Lucas DMPotentiating effect of the flavonolignan (-)-hydnocarpin in combination with vincristine in a sensitive and P-gp-expressing acute lymphoblastic leukemia cell line.Phytother Res 27 1735-8 11/1/2013
  • Bueno Pérez L, Li J, Lantvit DD, Pan L, Ninh TN, Chai HB, Soejarto DD, Swanson SM, Lucas DM, Kinghorn ADBioactive constituents of Indigofera spicata.J Nat Prod 76 1498-504 8/23/2013
  • Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MAStandard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Clin Pharmacokinet 52 705-12 8/1/2013
  • Gupta SV, Hertlein E, Lu Y, Sass EJ, Lapalombella R, Chen TL, Davis ME, Woyach JA, Lehman A, Jarjoura D, Byrd JC, Lucas DMThe proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Clin Cancer Res 19 2406-19 5/1/2013
  • Alachkar H, Santhanam R, Harb JG, Lucas DM, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G, Oaks JJ, Hickey CJ, Pan L, Kinghorn ADSilvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.J Hematol Oncol 6 21 1/1/2013
  • Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Patel TTherapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.PLoS One 8 e76136 1/1/2013
  • Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JCSelective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.Blood 120 4621-34 11/29/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu